Europese Unie - Nederlands - EMA (European Medicines Agency)

leo pharma a/s - brodalumab - psoriasis - immunosuppressiva - kyntheum is geïndiceerd voor de behandeling van matige tot ernstige plaque psoriasis bij volwassen patiënten die in aanmerking komen voor systemische therapie.

Europese Unie - Nederlands - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - spesolimab - psoriasis - immunosuppressiva - spevigo is indicated for the treatment of flares in adult patients with generalised pustular psoriasis (gpp) as monotherapy.

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

vsm geneesmiddelen b.v. berenkoog 35 1822 bh alkmaar - kalium bromatum d6 - tablet - , , , , , , , , , , , , , , , - datum verstrekking handelsvergunning:09 september 2003

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

ts products gelreweg 9 3843 an harderwijk - kalium bromatum trit. d6 250 mg/stuk - tablet - , , , , , , , , , , , , , , , , , , , , , , , - datum verstrekking handelsvergunning:23 september 2011

Europese Unie - Nederlands - EMA (European Medicines Agency)

kyowa kirin holdings b.v. - burosumab - hypophosphatemia, familial; hypophosphatemic rickets, x-linked dominant; osteomalacia - geneesmiddelen voor de behandeling van botziekten - crysvita is indicated for the treatment of x-linked hypophosphataemia, in children and adolescents aged 1 to 17 years with radiographic evidence of bone disease, and in adults. crysvita is indicated for the treatment of fgf23-related hypophosphataemia in tumour-induced osteomalacia associated with phosphaturic mesenchymal tumours that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults.

Europese Unie - Nederlands - EMA (European Medicines Agency)

astrazeneca ab - durvalumab - carcinoom, niet-kleincellige long - antineoplastische middelen - non-small cell lung cancer (nsclc)imfinzi as monotherapy is indicated for the treatment of locally advanced, unresectable non small cell lung cancer (nsclc) in adults whose tumours express pd-l1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum based chemoradiation therapy (see section 5. imfinzi in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic nsclc with no sensitising egfr mutations or alk positive mutations. small cell lung cancer (sclc)imfinzi in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer (es-sclc). biliary tract cancer (btc)imfinzi in combination with gemcitabine and cisplatin is indicated for the first line treatment of adults with unresectable or metastatic biliary tract cancer (btc). hepatocellular carcinoma (hcc)imfinzi in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc).

België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

boiron - kalium bromatum 5ch 1 % - globuli - 5ch - kalium bromatum 5ch 1 %

België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

boiron - kalium bromatum 7ch 1 % - globuli - 7ch - kalium bromatum 7ch 1 %

België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

boiron - kalium bromatum 9ch 1 % - globuli - 9ch - kalium bromatum 9ch 1 %

België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

boiron - kalium bromatum 15ch 1 % - globuli - 15ch - kalium bromatum 15ch 1 %